Оланзапин в профилактике и лечении тошноты и рвоты, связанной с химиотерапией

Оланзапин в профилактике и лечении тошноты и рвоты, связанной с химиотерапией

Автор: Румянцев А.А., Покатаев И.А., Федянин М.Ю., Тюляндина А.С., Трякин А.А., Тюляндин С.А.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Оригинальные исследования

Статья в выпуске: 3 т.8, 2018 года.

Бесплатный доступ

Тошнота и рвота (ТиР), развивающаяся на фоне химиотерапии, оказывает значимое влияние на повседневную жизнь онкологических пациентов, снижая ее качество. В данной статье проведен анализ современных рекомендаций по лечению и профилактике ТиР, а также данных об эффективности трехкомпонентных режимов профилактики ТиР, являющихся стандартом поддерживающей терапии у пациентов, получающих высокоэметогенную терапию. Подробно рассмотрены данные о различных аспектах применения нейролептика оланзапина - экономически доступного, мощного и безопасного средства профилактики и лечения ТиР на фоне высокоэметогенной химиотерапии. Оценены перспективные направления изучения данного препарата в онкологической практике, а также препятствия, мешающие его внедрению в рутинную клиническую практику российских онкологов.

Еще

Тошнота, рвота, химиотерапия, тошнота и рвота, индуцированные химиотерапией, оланзапин, апрепитант

Короткий адрес: https://sciup.org/140243827

IDR: 140243827   |   DOI: 10.18027/2224-5057-2018-8-3-21-30

Список литературы Оланзапин в профилактике и лечении тошноты и рвоты, связанной с химиотерапией

  • Griffin A.M., Butow P. N., Coates A. S., Childs A. M., Ellis P. M. et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 1996. Vol. 7. P. 189-195.
  • Владимирова Л.Ю., Гладков О. А., Когония Л. М., Королева И. А., Семиглазова Т. Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2017. Т. 7. С. 466-476.
  • Vladimirova L. Yu., Gladkov O. A., Kogoniya L. M., Koroleva I. A., Semiglazova T. Yu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniyu toshnoty i rvoty u onkologicheskikh bol’nykh. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2017. Vol. 7. P. 466-476 (In Russ.)
  • NCCN Clinical Practice Guidelines Version 1.2018. Antiemesis.
  • Hesketh P.J., Kris M. G., Grunberg S. M., Beck T., Hainsworth J. D. et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 1997. Vol. 15(1). P. 103-109.
  • Pollera C.F., Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Cancer. 1989. Vol. 64. P. 1117-1122.
  • Hesketh P., Navari R., Grote T., Gralla R., Hainsworth J. et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J. Clin. Oncol. 1996. Vol. 14. P. 2242-2249.
  • Roila F., Donati D., Tamberi S., Margutti G. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002. Vol. 10. P. 88-95.
  • Kris M.G., Gralla R. J., Clark R. A., Tyson L. B., O’Connell J.P. et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J. Clin. Oncol. 1985. Vol. 3. P. 1379-1384.
  • EMA Guideline On Non-Clinical And Clinical Development Of Medicinal Products For The Treatment Of Nausea And Vomiting Associated With Cancer Chemotherapy. Dec 14, 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500017746.pdf (accessed 01.05.2018).
  • Molassiotis A., Coventry P. A., Stricker C. T., Clements C. et al. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J. Pain Symptom Manage. 2007. Vol. 34(2). P. 148-159.
  • Jones D., Zhao F., Fisch M. J., Wagner L. I., Patrick-Miller L.J. et al. The validity and utility of the M. D. Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin. Genitourin. Cancer. 2014. Vol. 12(1). P. 41-49.
  • Hesketh P.J., Grunberg S. M., Gralla R. J. et al. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of ChemotherapyInduced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin -The Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 2003. Vol. 21. No. 22. P. 4112-4119.
  • Poli-Bigelli S., Rodriques-Pereira J., Carides A. D. et al. Addition of the Neurokinin 1 Receptor Antagonist Aprepitant to Standard Antiemetic Therapy Improves Control of Chemotherapy-Induced Nausea and Vomiting. Cancer. 2003. Vol. 97. P. 3090-3098.
  • Warr D.G., Hesketh P. J., Gralla R. J. et al. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy. J. Clinical Oncology. 2005. Vol. 23. P. 2822-2830.
  • Grunberg S., Chua D., Maru A. et al. Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol -EASE. J. Clin. Oncol. 2011. Vol. 29(11). P. 1495-1501.
  • Hesketh P.J., Rossi G., Rizzi G., Palmas M., Alyasova A. et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Annals of Oncology. 2014. Vol. 25. P. 1340-1346.
  • Rapoport B.L., Chasen M. R., Gridelli C., Urban L., Modiano M. R. et al. Safety and effi cacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015. Vol. 16(9). P. 1079-1089.
  • Suzuki K., Yamanaka T., Hashimoto H., Shimada Y., Arata K. et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Annals of Oncology. 2016. Vol. 27. P. 1601-1606.
  • Инструкция по медицинскому применению лекарственного препарата оланзапин от 15.10.2017. Государственный реестр лекарственных средств. Доступно по адресу http://grls.rosminzdrav.ru. Последний доступ 01.04.2018.
  • Instruction for the medical use of olanzapine. Available at: http://grls.rosminzdrav.ru (accessed 01.04.2018) (In Russ.)
  • Chow R., Chiu L., Navari R., Passik S., Chiu N. et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016. Vol. 24(2). P. 1001-1008.
  • Navari R.M., Gray S. E., Kerr A. C. et al. Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial. J. Support Oncol. 2011. Vol. 9. P. 188-195.
  • Navari R.M., Nagy C. K., Le-Rademacher J., Loprinzi C. L. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J. Community Support Oncol. 2016. Vol. 14(4). P. 141-147.
  • Navari R.M., Qin R., Ruddy K. J., Liu H., Powell S. F. et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N. Engl. J. Med. 2016. Vol. 375. P. 134-142.
  • Yanai T., Iwasa S., Hashimoto H., Ohyanagi F., Takiguchi T. et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int. J. Clin. Oncol. 2018. Vol. 23(2). P. 382-388.
  • Mizukami N., Yamauchi M., Koike K., Watanabe A., Ichihara K. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J. Pain Symptom Manage. 2014. Vol. 47(3). P. 542-550.
  • Cleeland C.S., Mendoza T. R., Wang X. S., Chou C., Harle M. T. et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer. 2000. Vol. 89. P. 1634-1646.
  • Zhang Z., Zhang Y., Chen G., Hong S., Yang Y. et al. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor AntagonistBased Triple Regimens in Preventing ChemotherapyInduced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist. 2018. Vol. 23(5). P. 603-616.
  • Navari R., Nagy C. K., Gray S. E. et al. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapyinduced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013. Vol. 21. P. 1655-1663.
  • Yoodee J., Permsuwan U., Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2017. Vol. 112. P. 113-125.
  • Brunton L., Chabner B. A., Knollman B. et al. Pharmacotherapy of Psychosis and Mania. In: Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw-Hill Education LLC., 2011. P. 428-440.
  • Hirsch L., Yang J., Bresee L., Jette N., Patten S. et al. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf. 2017. Vol. 40(9). P. 771-781.
  • Zhang Y., Liu Y., Su Y., You Y., Ma Y. et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017. Vol. 17(1). P. 373.
  • Anil S.S., Ratnakaran B., Suresh N. et al. A case report of rapid-onset hyponatremia induced by low-dose olanzapine. J. Family Med. Prim. Care. 2017. Vol. 6(4). P. 878-880.
  • Kast R.E., Foley K. F. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur. J. Cancer Care (Engl). 2007. Vol. 16(4). P. 351-354.
  • Del Cadia M., De Rienzo F., Weston D. A., Thompson A. J., Menziani M. C. et al. Exploring a potential palonosetron allosteric binding site in the 5-HT3 receptor. Bioorg. Med. Chem. 2013. Vol. 21(23). P. 7523-7528.
  • Ito Y., Tsuda T., Minatogawa H., Kano S., Sakamaki K. et al. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High Emetogenic Chemotherapy. J. Clinical Oncology .
  • Абрамов М.Е., Болотина Л. В., Булавина И. С., Возный Э. К., Горубунова В.А и др. Клинические рекомендации по профилактике и лечению тошноты и рвоты у больных, получающих химио-и лучевую противоопухолевую терапию. Ассоциация Онкологов России. Москва, 2014. 26 стр. Доступно по адресу: http://www.oncology.ru/association/clinical-guidelines/2014/49.pdf. Последний доступ 15.05.2018.
  • Abramov M. E., Bolotina L. V., Bulavina I. S., Voznyi E. K., Gorubunova V.A et al. Klinicheskie rekomendatsii po profilaktike i lecheniyu toshnoty i rvoty u bol’nykh, poluchayushchikh khimio-i luchevuyu protivoopukholevuyu terapiyu (Clinical recommendations for the prevention and treatment of nausea and vomiting in patients receiving chemo-and radiation antitumor therapy). Assotsiatsiya Onkologov Rossii (Association of Russian Oncologists). Moscow, 2014. 26 p. (In Russ.)
  • Hesketh P.J., Kris M. G., Basch E., Bohlke K., Barbour S. Y. et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2017. Vol. 35(28). P. 3240-3261.
Еще
Статья научная
SciUp 2024 © 2024 ©